S17 Ep31: ASCO 2026 Plenary: RASolute 302

About this episode

This episode reviews the RASolute 302 trial and its implications for treating metastatic pancreatic adenocarcinoma.

Two Onc Docs , hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago. In this episode, OncLive On Air ® partnered with Two Onc Docs to provide a comprehensive review of data from the phase 3 RASolute 302 trial (NCT06625320), a landmark study presented at the 2026 ASCO Annual Meeting that has established daraxonrasib (RMC-6236) as the new standard of care (SOC) for the second-line treatment of patients with metastatic pancreatic adenocarcinoma. The discussion began by highlighting the historical context of second-line treatment, where standard chemotherapy options like FOLFOX (leucovorin calcium, fluorouracil, and oxaliplatin) or gemcitabine-based regimens typically yielded a median overall survival (OS) of only approximately 6 to 7 months. Although RAS…

People in this episode

Hosts: Samantha A. Armstrong, MD, Karine Tawagi, MD

Topics covered

• oncology
• pancreatic cancer
• clinical trials
• RAS mutations
• treatment standards

Keywords

• RASolute 302
• daraxonrasib
• pancreatic adenocarcinoma
• ASCO 2026
• oncology treatment

Mentioned in this episode

Organizations: Indiana University Health, University of Illinois

Products: daraxonrasib (RMC-6236)

More episodes of OncLive® On Air

• S17 Ep32: Previewing Key Myeloma Presentations to Watch at EHA 2026: With Joshua Richter, MD · June 10, 2026 · 10 min
• S17 Ep30: Tumor Board: Clinical Integration of Molecular Profiling in Glioma—Transforming the Use of Targeted Therapy · June 5, 2026 · 32 min
• S17 Ep29: Navigating Radiation, Systemic Therapy, and Multidisciplinary Care in Skin Cancer: With Hirsch Matani, MD; Elizabeth Zhang-Velten, MD, PhD; and Binh T. Ngo, MD · June 1, 2026 · 30 min
• S17 Ep28: In-House Molecular Testing in NSCLC Improves Turnaround Time, Tissue Stewardship, and Multidisciplinary Coordination: Featuring Anthony Chi, MD; Monica Peravali, MD; and Archana Jadhav, MD · May 28, 2026 · 30 min
• S17 Ep27: Advances in Cervical Cancer: Prevention, Immunotherapy, and the Rise of Antibody-Drug Conjugates: With Ursula A. Matulonis, MD; and Meghan E. Shea, MD · May 27, 2026 · 16 min
• S17 Ep26: Emerging Targets, Second-Line Standards, and Molecular Subtyping Signal a New Era in SCLC Care: With Jacob Sands, MD · May 26, 2026 · 25 min